apexian pharmaceuticals

But, until now, the question of “how” remained unanswered. Apexian Pharmaceuticals's main competitors include 3sbio, Takeda Oncology, Shanghai Junshi Biosciences and Jiangsu Hansoh Pharmaceutical Group. As President, CEO, he built the company to be a unique discovery engine with multiple projects at the IND-enabling stage. Apexian Pharmaceuticals,’ latest studies in collaboration with Indiana University’s Simon Cancer Center investigator Dr. Reuben Kapur show promise for halting that transformation. The Global Ophthalmics Partnering 2014-2022 report provides comprehensive access to available deals and contract documents for over 550 ophthalmics deals signed between the … Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs. Mark R. Kelley, Apexian Pharmaceuticals’ chief scientific officer, is the Betty and Earl Herr Chair in Pediatric Oncology Research and a professor in the Department of Biochemistry and Molecular Biology and the … Resources. SBI Capital Markets. Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. El informe de investigación incluye segmentos específicos por región (país), por fabricantes, por Tipo y por Aplicación. Apexian Pharmaceuticals’s official website is www.apexianpharma.com Posted October 30, 2021 by Ryan Piurek. Get Apexian Pharmaceuticals can be contacted at (844) 463-3330. Apexian was founded on the work of Mark Kelley, who identified a unique protein that drives the growth of cancer cells. 194 Pharmaceutical jobs available in American Fork, UT on Indeed.com. Apexian Pharmaceuticals Inc., a biotechnology company focused on developing novel compounds to treat cancer, has licensed all available patented and patent-pending technology discovered in Mark R. Kelley's laboratory at the Indiana University School of Medicine. On January 24, 2018 Apexian Pharmaceuticals, a clinical-stage biopharmaceutical company, has reported the opening of a clinical trial for patients with advanced solid tumors (Press release, Apexian Pharmaceuticals, JAN 24, 2018, View Source [SID1234523543]). Company officials announced that the U.S. Food and Drug Administration has agreed that APX3330, the … Free and open company data on Utah (US) company ZION PHARMACEUTICALS, LLC (company number 11419785-0160), 44 MAIN STREET AMERICAN FORK, UT 84003-2318 The global leader in press release distribution and regulatory disclosure. Apexian Pharmaceuticals’s headquarters are in 20 N. Meridian, Ste 801, Indianapolis, Indiana, 46204, United States What is Apexian Pharmaceuticals’s phone number? Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Apexian's research is grounded and driven by the belief that "better is always possible. Digital Edition; Purchase Past Issues Find jobs at Apexian Pharmaceuticals. Apexian Pharmaceuticals Appoints CEO. Products. It focuses on inflammatory disorders and tumorigenesis, including cancers of the colon, pancreas, skin, blood, diabetic macular edema. The company's filing status is listed as Active and its File Number is 2008043000664. Alexion Pharmaceuticals, Inc. 3w. Apexian Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. apexian pharmaceuticals inc. apexian pharmaceuticals. Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. For nearly two decades, Biocrossroads has established itself as a leader in helping to build Indiana’s life sciences sector and a major source of venture capital for Indiana-based life sciences startups. Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. Apexian Pharmaceuticals. On Aug 31, 2021 Apexian Pharmaceuticals closed a Venture – Series Unknown round and raised $100,000 from IU Ventures, featuring lead investors IU Ventures. Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. Tamaño del mercado global Tratamiento de neuropatía periférica inducida por quimioterapia 2022 Investigación por oportunidades comerciales, participación en la industria, tasa de crecimiento, análisis regional, fabricación superior como Lanzatech, Yancheng Hongtai Bioengineering, Yancheng Huade Biological y pronóstico para 2028 Products. Compare Apexian Pharmaceuticals to its competitors by revenue, employee growth and other metrics at Craft. Apexian Pharmaceuticals is currently hiring for a range of positions Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia in Preclinical Models Published: Dec 12, 2018 INDIANAPOLIS--( BUSINESS WIRE )-- Apexian Pharmaceuticals, is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Mercato Trattamento della neuropatia periferica indotta dalla chemioterapia Dimensioni del mercato 2022, analisi delle azioni, crescita, tendenze recenti, opportunità di business fino al 2028 Pricing. - Indianapolis, Indiana-based cancer therapeutics developer Apexian Pharmaceuticals is closing its series A financing round, the company said. Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others. apexian pharmaceuticals inc. apexian pharmaceutical , inc. apexian pharmaceuticals, inc. Start Free Trial . 26 Benefits. It commercializes intellectual property discovered at the Indiana University School of Medicine. Tag: Apexian Pharmaceuticals Connecting capital to ideas and collaborating to ignite Indiana’s entrepreneurial ecosystem. Dublin, June 14, 2022 (GLOBE NEWSWIRE) -- The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Find useful insights on Apexian Pharmaceuticals’s employee, technology stack, location, news alerts and more at Slintel. Apexian Pharmaceuticals – Elevate Ventures Apexian Pharmeceuticals About Apexian is a biotechnology company focused on developing novel compounds to treat cancer. Solutions. Whalewisdom has at least 1 13G filings The firm last filed a Form D notice of exempt offering of securities on 2019-03-25. Congratulations to Apexian Pharmaceuticals, which licenses technology through the Indiana University Innovation and Commercialization Office. Food and Drug Administration (FDA) Covenant Surgical Partners. Current Portfolio Companies Apexian Pharmaceuticals, Inc. Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target. An obscure sliver of RNA with a grim-sounding name is unexpectedly taking center stage as a linchpin in transforming pre-leukemic cells into full-blown leukemia. A group of medical researchers, many of whom are Eli Lilly refugees with powerful pharmaceutical experience, share a common goal of wiping out cancer. Genetic mutations by themselves are rarely enough to … www.apexianpharma.com Formerly Known As Apex Therapeutics Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 20 North Meridian Street Suite 801 Indianapolis, IN 46204 United States +1 (317) 000-0000 Roberta received a Bachelor of Arts degree from University Of Indianapolis. About the company: Apexian Pharmaceuticals is located at United States, North America. Company Description: Apexian Pharmaceuticals, Inc. is located in Indianapolis, IN, United States and is part of the Scientific Research and Development Services Industry. Where We Are. Get Apexian Pharmaceuticals can be contacted at (844) 463-3330. Ping An Ventures. DUBLIN--(BUSINESS WIRE)--The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.. Neurological Disorders $33B+ Gene Therapy $24B+ Autoimmune Disease $30B+ Metabolic Disorders $18B+ Clinical Dashboards. Posted October 30, 2021 by Ryan Piurek. Phone Number (317) 684-9106 Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target. 20 North Meridian Street Indianapolis Indiana 46204 There are no jobs right now, but check back soon as we update jobs daily. Berlin (Germany) – Der Behandlung der durch Chemotherapie induzierten peripheren Neuropathie-Marktforschungsbericht enthält eine detaillierte Analyse, die auf gründlichen Untersuchungen des Gesamtmarkts basiert, insbesondere zu Fragen, die an die Marktgröße, das Wachstumsszenario, die potenziellen Chancen, die Betriebslandschaft, die … Use Slintel to connect with top decision-makers at Apexian Pharmaceuticals. Whalewisdom has at least 1 13G filings The firm last filed a Form D notice of exempt offering of securities on 2019-03-25. ICH GCP. The Company focuses in developing novel compounds to treat cancer including tumors of the colon, lung, breast, and pancreas. Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. This represents 7.136 percent ownership of the company. The study involves APX3330, an orally administered inhibitor of APE1/Ref-1, a dual-function protein that plays a … Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. Apexian Pharmaceuticals has raised $4.81 m in total funding View Company Get notified regarding key financial metrics and revenue changes at Apexian Pharmaceuticals Learn more Apexian Pharmaceuticals Funding Summary Metrics Apexian Pharmaceuticals's latest funding round in November 2016 was reported to be $1.3 m. Pricing. Weekly Paper. Apexian Pharmaceuticals is a biotechnology company that provides medicines for cancer. Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all … It focuses on inflammatory disorders and tumorigenesis, including cancers of the colon, pancreas, skin, blood, diabetic macular edema. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the … Their latest funding was raised on Aug 31, 2021 from a Venture - Series Unknown round. -Regenacy Pharmaceuticals-MAKScientific LLC-Metys Pharmaceuticals AG-Nemus Bioscience Inc-PledPharma-Sova Pharmaceuticals Inc-DermaXon LLC-Kineta Inc-Krenitsky Pharmaceuticals Inc-PeriphaGen-Apexian Pharma Roberta Smithey is a Director, Regulatory Affairs at Apexian Pharmaceuticals based in Indianapolis, Indiana. Apexian Pharmaceuticals United States of America. Apexian Pharmaceuticals is a patient-centered biotechnology company dedicated to developing novel compounds that target the APE1 protein in multiple indications, including cancer. Apply to Pharmacy Technician, Analyst, Pharmaceutical Sales Representative and more! PRO Data . Compare Apexian Pharmaceuticals to its competitors by revenue, employee growth and other metrics at Craft. Resources. Resources. Apexian Pharmaceuticals, a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs, is pleased to announce that its Chief Scientific Officer, Mark Kelley, PhD, was recognized as an outstanding scholar and researcher during the annual IUPUI Chancellor's Academic Honors Convocation … Find jobs at Apexian Pharmaceuticals. VISIT WEBSITE Apexian Pharmaceuticals is funded by 3 investors. Congratulations to Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company that is developing novel compounds to treat cancer. Prior to Apexian Therapeutics, Marty founded Amphora Discovery Corporation in September 2001. Home. Where We Are. Consulting or Advisory Role: Apexian Pharmaceuticals, Ocuphire Pharma. Apexian Pharmaceuticals is based out of Indianapolis. Apexian Pharmaceuticals at 20 N Meridian St, Indianapolis, IN 46204. Explore Apexian Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! Centro de Investigacion Sanitaria; Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri; Centro Studi Internazionali, Italy; Cervical Artery Dissections and Ischemic Stroke Patients … We are innovators, leaders, and collaborators. Search Crunchbase. Previously, Roberta was a Director, R egulatory Affairs at The Medicines and also held positions at Novartis, Pearl Pathways, Targanta Therapeutics, Eli Lilly. Explore Apexian Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! Apexian’s research is grounded and driven by the belief that “better is … Tag: Apexian Pharmaceuticals Connecting capital to ideas and collaborating to ignite Indiana’s entrepreneurial ecosystem. Apexian Pharmaceuticals is currently hiring for a range of positions Apexian Pharmaceuticals is based out of Indianapolis. Steve Carchedi will speak to students on the impact of current health policy on pharmaceutical and life sciences companies, the differences between the biotech industry and the traditional pharmaceutical industry, and give advice on a career path in healthcare. Solutions. … Apexian Pharmaceuticals, an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, announced today … Start Free Trial . Apexian Pharmaceuticals at 20 N Meridian St, Indianapolis, IN 46204. Apexian Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. Hi, we’re Apexian Pharmaceuticals. Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. Apexian Pharmaceuticals is a biotechnology company that provides medicines for cancer. Alexion Pharmaceuticals has become aware of scams from individuals, organizations, and Internet sites claiming to represent Alexion in recruitment activities in return for disclosing financial information. La segmentación del mercado crea subconjuntos de un mercado según el tipo de producto, el usuario final o la aplicación, la geografía y otros factores. Leadership: Apexian Pharmaceuticals. INDIANAPOLIS–(BUSINESS WIRE)–Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Proceeds will be used to initiate a phase 1 clinical study for the company's lead molecule, APX3330, a novel first-in-class oral treatment for patients with cancer. Apexian Pharmaceuticals, Inc. has 4 total employees across all of its locations and generates $268,176 in sales (USD). The company offers APX3330, a drug candidate that targets the APE1/Ref-1 redox protein, a molecule found in a number of cancers. Search Crunchbase. Biography Steve, who was named CEO in 2016, was previously Chief Executive Officer and President of Cornerstone Pharmaceuticals, an oncology discovery and development company focused on cancer metabolism. 39,451 Total Employees. -Krenitsky Pharmaceuticals Inc-PeriphaGen-Apexian Pharma-WinSanTor. 20 North Meridian Street Indianapolis Indiana 46204 There are no jobs right now, but check back soon as we update jobs daily. Apexian Pharmaceuticals's main competitors include 3sbio, Takeda Oncology, Shanghai Junshi Biosciences and Jiangsu Hansoh Pharmaceutical Group. Get Apexian Pharmaceuticals rKaufman & Lynd reviews, rating, hours, phone number, directions and more. Genetic mutations by themselves are rarely enough to flip the switch. Kliniske forsøg for segraves, r., t., m.d., ph.d.. Kliniske forsøgsregister. (Sales figure is modelled). The Registered Agent on file for this company is Barnard Associates Inc and is located at 20 N Meridian St Ste 801, Indianapolis, IN 46204. Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. Public relations and investor relations professionals rely on Business Wire for … INDIANAPOLIS--(BUSINESS WIRE)-- Apexian Pharmaceuticals, Inc., an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, announced today that they are closing their Series A round.This financing follows previous investments as well as numerous grants and awards by the company since its founding. And they just might do that. Apexian Pharmaceuticals has raised a total of $6.9M in funding over 8 rounds. He then served in the Vice Chairman role from January of 2005 until January 2007. Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia. It commercializes intellectual property discovered at the Indiana University School of Medicine. They have now developed a drug that targets this protein and is in … Career opportunities are published only … The latest litigation news involving the company Apexian Pharmaceuticals Inc. () Apexian Pharmaceuticals corporate office is located in 20 N. Meridian, Ste 801, Indianapolis, Indiana, United States and has 5 employees. Get Apexian Pharmaceuticals rKaufman & Lynd reviews, rating, hours, phone number, directions and more. Apexian Pharmaceuticals, Inc. ownership in OCUP / Ocuphire Pharma Inc 2021-03-26 - Apexian Pharmaceuticals, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 779,993 shares of Ocuphire Pharma Inc (US:OCUP). It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. Apexian Pharmaceuticals is a patient-centered biotechnology company dedicated to developing novel anti-cancer compounds that target the multiple functions of the APE1 protein. Apexian Pharmaceuticals serves patients in the State of Indiana. Hi, we’re Apexian Pharmaceuticals. Apexian Pharmaceuticals, Inc. is an Indiana Foreign For-Profit Corporation filed On April 29, 2008. Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Apexian Pharmaceuticals is Drug Discovery in United States that focus on related macular degeneration business. Apexian Pharmaceuticals is a clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose work on the APE1/Ref-1 protein has provided unique insight into this important biological target. Monday, October 24, 2016 12:06 PM EDT Updated: Wednesday, June 23, 2021 11:02 PM EDT. IBJ.com Apexian Pharmaceuticals news. Dublin, June 14, 2022 (GLOBE NEWSWIRE) -- The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.. PRO Dashboards. Narayana Nethralaya Foundation. In January 2022, Ocuphire Pharma entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all … Inflammation also plays a role. By Tara Twigg. Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. Chrome Extension. For nearly two decades, Biocrossroads has established itself as a leader in helping to build Indiana’s life sciences sector and a major source of venture capital for Indiana-based life sciences startups. Apexian Pharmaceuticals is a clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose work on the APE1/Ref-1 protein has provided unique insight into this important biological target. Congratulations to Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company that is developing novel compounds to treat cancer. Resources. Stock and Other Ownership Interests: Apexian Pharmaceuticals. To learn more about Apexian Pharmaceuticals, please visit the company's website at www.ApexianPharma.com Contacts Apexian Pharmaceuticals Roger Miller, 844-463-3330 x113 Email: PR@Apexianpharma.com Eversana. BLP Management. Apexian Pharmaceuticals’s phone number is (317) 684-9196 What is Apexian Pharmaceuticals’s official website? Popular Searches Apexian Pharmaceuticals Inc Apexian Pharmaceuticals The Company focuses in developing novel compounds to treat cancer including tumors of … Founded in 2008. Posted on 12/19/2018 72 . IU Ventures and … Chrome Extension. Company officials announced that the U.S. Food and Drug Administration has agreed that APX3330, the … Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. GHO Capital. Explore Apexian Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! Indiana University Research and Technology Corp., which protects, markets and licenses …

Camping Near Abraham Lincoln Birthplace, Powerball Numbers 1/26/22, How To Rent Out Your First House, Amniotic Fluid Color Abnormalities, Lexus License Plate Ideas, Blissful Barding Ffxiv, Go Train To Ontario Science Center, Georgia School Safety Conference 2022, Land For Sale Newry, Maine, Galaxy Buds Plus Case Battery, Jess Glynne Take Me Home,